MedTrace Logo

Oral Nadolol for the Treatment of Adults With Mild Asthma

NCT00670267 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-05-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Conditions

Interventions

DRUG

nadolol

Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.

Sponsors & Collaborators

  • University of Houston

    collaborator OTHER

  • Sandler Program for Asthma Research

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Invion, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicola A Hanania, MD · University of Houston

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670267 on ClinicalTrials.gov